GlassScriptPhysician profile
Sonia J Lopez
NPI 1134281975
$14,024.38
in general payments reported to CMS, 2019-2025
20 companies · $8,883 in 2025
The $8,883 reported for 2025 was more than what 97% of Addiction Medicine (Family Medicine) providers received nationally (typical 2025 total: $143).
See the full distribution for Addiction Medicine (Family Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $330 · 2020: $526 · 2021: $1,881 · 2022: $655 · 2023: $789 · 2024: $960 · 2025: $8,883.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,500 · Food and Beverage: $2,129 · Education: $3.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,500.00 |
| Food and Beverage | $2,129.15 |
| Education | $3.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $9,083.48 | 2020-2025 | Epclusa |
| Alkermes, INC. | $2,349.10 | 2019-2024 | Vivitrol, Vivitrol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,403.25 | 2021-2025 | Relistor |
| Indivior INC. | $163.30 | 2019-2024 | Sublocade |
| Abbvie INC. | $162.77 | 2022-2023 | |
| Janssen Biotech, INC. | $159.90 | 2020-2023 | Symtuza |
| Braeburn INC. | $146.54 | 2025 | Brixadi |
| Orexo US, INC. | $129.09 | 2022-2024 | Zubsolv |
| Neurocrine Biosciences, INC. | $95.57 | 2021-2024 | Ingrezza |
| Viiv Healthcare Company | $46.95 | 2024 | Dovato, Rukobia |
| Paratek Pharmaceuticals, INC. | $43.68 | 2025 | Nuzyra |
| Teva Pharmaceuticals USA, INC. | $41.00 | 2020 | |
| Ibsa Pharma INC. | $39.06 | 2024 | Tirosint, Licart, Flector |
| Pfizer INC. | $34.44 | 2023 | |
| Lundbeck LLC | $29.11 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $24.41 | 2024 | Gardasil, Capvaxive, Gardasil 9 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.58 | 2023 | Jardiance, Synjardy |
| Otsuka America Pharmaceutical, INC. | $21.42 | 2020 | |
| Uswm, LLC | $16.01 | 2024 | Lucemyra |
| Napo Pharmaceuticals INC | $12.72 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonia Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.